Definitive Healthcare Corp.

Listed Company

DHCIK 0001861795NasdaqAcceleratedSmaller ReportingServices-Prepackaged SoftwareDelawareFY ends Dec 31

Period

FY 2025

Revenue

$241.52M

Net Income

$-138.93M

Total Assets

$735.49M

Equity

$378.99M

Shares Out

104.47M

Op. Cash Flow

$53.78M

Business

Definitive Healthcare Corp. provides healthcare commercial intelligence via a software-as-a-service platform that helps customers make data-driven commercial decisions across the healthcare ecosystem. It offers comprehensive provider and market datasets, analytics, AI-driven insights, and workflow modules to support product development, go-to-market planning, sales targeting, and customer success. Its business is organized around its SaaS platform, proprietary data and data-engine capabilities, AI/machine-learning analytics, and customer experience and sales functions. The company serves U.S. healthcare markets and related sectors—such as life sciences, HCIT, providers, and other commercial organizations—primarily through its SaaS distribution, inside sales, marketing, and customer success channels.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	242	252	251	223	166
Cost of revenue exclusive of amortization	38	41	35	26	19
Amortization	20	14	13	17	21
Gross profit	183	197	204	180	125
Sales and marketing	82	84	95	90	56
Product development	35	37	42	35	19
General and administrative	52	49	59	52	33
Depreciation and amortization	36	38	39	40	39
Transaction, integration, and restructuring expenses	8	12	12	8	6
Goodwill impairment	196	689	287	0	0
Total operating expenses	408	908	534	224	153
Loss from operations	−224	−711	−330	−44	−27
Interest income	7	15	14	3	29,000
Interest expense	−11	−15	−15	−11	−26
Gain on remeasurement of TRA liability	22	77	23	10	—
Loss on partial extinguishment of debt	−500,000	0	0	0	−10
Other (expense) income, net	−2	411,000	−291,000	862,000	294,000
Total other income, net	15	77	22	2	−35
Loss before income taxes	−209	−634	−308	−42	−63
Benefit from income taxes	10	42	19	18	443,000
Net loss	−199	−591	−290	−24	−62
Less: Net loss attributable to noncontrolling interests	−60	−178	−87	−17	−10
Net loss attributable to Definitive Healthcare Corp.	−139	−413	−202	−7	−18
Basic (per share)	−1.3	−3.54	−1.79	−0.07	−0.19
Diluted (per share)	−1.3	−3.54	−1.79	−0.07	−0.19
Basic (shares)	107	117	113	101	92
Diluted (shares)	107	117	113	101	92

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	164	105	131	147	387
Short-term investments	17	185	177	185	0
Accounts receivable, net	52	53	59	59	43
Prepaid expenses and other assets	12	13	13	13	7
Deferred contract costs	13	14	13	10	7
Total current assets	258	370	394	414	444
Property and equipment, net	13	4	4	4	5
Operating lease right-of-use assets, net	5	8	10	10	0
Other assets	2	2	2	5	8
Deferred contract costs	13	14	17	15	12
Intangible assets, net	247	298	323	351	352
Goodwill	197	393	1,075	1,325	1,263
Total assets	735	1,089	1,826	2,123	2,116
Accounts payable	4	11	6	4	5
Accrued expenses and other liabilities	45	41	52	27	—
Deferred revenue	97	93	97	100	84
Term loan	9	14	14	9	7
Operating lease liabilities	3	2	2	2	0
Total current liabilities	157	161	171	141	118
Deferred revenue	2	32,000	9,000	236,000	412,000
Term loan	156	229	243	256	264
Operating lease liabilities	5	8	9	10	0
TRA liability	19	50	127	155	154
Deferred tax liabilities	15	25	67	76	76
Other liabilities	2	9	10	3	1
Total liabilities	357	482	627	641	613
Commitments and Contingencies (Note 15)	—	—	—	—	—
Additional paid-in capital	1,062	1,085	1,087	970	891
Accumulated other comprehensive deficit	−1	−610,000	2	4	62,000
Accumulated deficit	−780	−641	−227	−25	−18
Noncontrolling interests	98	163	338	533	630
Total equity	379	607	1,199	1,482	1,503
Total liabilities and equity	735	1,089	1,826	2,123	2,116

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	3	2	2	2	2
Amortization of intangible assets	53	49	50	55	58
Amortization of deferred contract costs	16	15	13	9	5
Equity-based compensation	29	38	49	36	10
Amortization of debt issuance costs	519,000	702,000	702,000	702,000	2
Write-off of deferred offering costs	467,000	0	0	—	—
(Recovery of) provision for bad debt expense	−232,000	947,000	1	1	—
Non-cash restructuring charges	595,000	1	155,000	—	—
TRA remeasurement	−22	−77	−23	−10	−151,000
Changes in fair value of contingent consideration	−4	−2	302,000	1	4
Deferred income taxes	−11	−43	−19	−18	−436,000
Accounts receivable	1	6	811,000	−13	−11
Prepaid expenses and other assets	−2	−8	−7	−127,000	−4
Deferred contract costs	−13	−13	−19	−15	−14
Contingent consideration	0	−602,000	0	−6	0
Accounts payable, accrued expenses and other liabilities	−1	−5	1	3	3
Deferred revenue	6	−5	−7	13	23
Net cash provided by operating activities	54	58	41	36	25
Purchases of property, equipment and other assets	−17	−12	−3	−8	−7
Purchases of short-term investments	−64	−304	−259	−338	0
Maturities of short-term investments	235	304	275	154	0
Cash paid for acquisitions and investments, net of cash acquired	0	−14	−45	−56	−40
Net cash provided by (used in) investing activities	154	−26	−32	−249	−47
Repayments of term loans	−253	−14	−9	−7	—
Proceeds from term loan	175	0	0	—	—
Payments of debt issuance costs	−2	0	0	0	−4
Taxes paid related to net share settlement of equity awards	−5	−8	−4	−4	0
Repurchases of Class A common stock	−49	−22	0	0	—
Payments of contingent consideration	0	−1	0	−1	−2
Payments under TRA	−14	−7	−246,000	0	0
Payments of equity offering issuance costs	0	0	−30,000	−2	−12
Member distributions	−3	−5	−12	−13	−8
Net cash used in financing activities	−151	−57	−26	−27	384
Net increase (decrease) in cash and cash equivalents	57	−25	−16	−240	363
Effect of exchange rate changes on cash and cash equivalents	1	−636,000	218,000	−544,000	−129,000
Interest	11	14	14	10	14
Income taxes	833,000	0	100,000	0	0
Net assets acquired, net of cash acquired	0	14	53	97	14
Working capital adjustment receivable	0	−145,000	145,000	0	−145,000
Contingent consideration	0	0	−8	−1	0
Net cash paid for acquisitions	0	14	45	56	14
Capital expenditures included in accounts payable and accrued expenses and other liabilities	5	7	47,000	1	7

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro